XML 107 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)
€ in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
EUR (€)
Dec. 31, 2022
EUR (€)
Dec. 31, 2021
EUR (€)
Dec. 31, 2023
USD ($)
Jul. 31, 2020
EUR (€)
Notes to the Consolidated Statements of Operations          
Upfront and milestones payments included in contract liabilities € 92,680 € 107,308      
Revenue recognized from upfront and milestones payments 31,051 44,787 € 67,828    
GSK          
Notes to the Consolidated Statements of Operations          
Upfront Payments Received Or Receivable 220,000       € 120,000
Upfront and milestones payments included in contract liabilities 88,715 102,804      
Revenue recognized from upfront and milestones payments 29,089 42,690 51,728    
Boehringer Ingelheim          
Notes to the Consolidated Statements of Operations          
Upfront Payments Received Or Receivable 30,000        
Revenue recognized from upfront and milestones payments     14,003    
Genmab          
Notes to the Consolidated Statements of Operations          
Upfront Payments Received Or Receivable 8,937     $ 10,000  
Upfront and milestones payments included in contract liabilities 2,383 3,575      
Revenue recognized from upfront and milestones payments 1,192 1,787 1,787    
CRISPR          
Notes to the Consolidated Statements of Operations          
Upfront Payments Received Or Receivable 3,947     $ 4,500  
Upfront and milestones payments included in contract liabilities 1,582 929      
Revenue recognized from upfront and milestones payments € 770 € 310 € 310